Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

Carrie A. Thompson, Herve Ghesquieres, Matthew J. Maurer, James R. Cerhan, Pierre Biron, Stephen M. Ansell, Catherine Chassagne-Clément, David J. Inwards, Thérèse Gargi, Patrick B. Johnston, Emmanuelle Nicolas-Virelizier, William R. Macon, Marie Peix, Ivana N. Micallef, Catherine Sebban, Grzegorz S. Nowakowski, Luis F. Porrata, George J. Weiner, Thomas E. Witzig, Thomas M. HabermannBrian K. Link

Research output: Contribution to journalArticle

93 Scopus citations

Abstract

Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.

Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.

Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).

Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.

Original languageEnglish (US)
Pages (from-to)3506-3512
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number31
DOIs
StatePublished - Nov 1 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Thompson, C. A., Ghesquieres, H., Maurer, M. J., Cerhan, J. R., Biron, P., Ansell, S. M., Chassagne-Clément, C., Inwards, D. J., Gargi, T., Johnston, P. B., Nicolas-Virelizier, E., Macon, W. R., Peix, M., Micallef, I. N., Sebban, C., Nowakowski, G. S., Porrata, L. F., Weiner, G. J., Witzig, T. E., ... Link, B. K. (2014). Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. Journal of Clinical Oncology, 32(31), 3506-3512. https://doi.org/10.1200/JCO.2014.55.7561